CYPHERPUNK TECHNOLOGIES INC. (CYPH) Form 8-K — Aug 12, 2026
Cypherpunk Technologies (Nasdaq: CYPH) reported second quarter 2026 net income of $39.4 million, or $0.18 per diluted share, versus a net loss of $16.6 million a year earlier, driven by a $46.0 million unrealized gain on its Zcash treasury as ZEC rose from $243.35 to $400.09 during the quarter. As of August 11, 2026, Cypherpunk held 323,394.38 ZEC — roughly 1.92% of circulating Zcash supply — at an average purchase price of $341.83, valued at $129.4 million at quarter end, against just $7.6 million in cash.
Key figures
- Eps
- $0.18 diluted / $0.21 basic (Q2 2026)
- Net Income
- $39.4 million (Q2 2026) vs. net loss of $16.6 million (Q2 2025)
- Total Debt
- $3.7 million total liabilities (June 30, 2026)
- Total Assets
- $143.0 million (June 30, 2026)
- Cash Position
- $7.6 million (June 30, 2026) vs. $14.0 million (Dec 31, 2025)
- Shares Outstanding
- 107764382
- Zec holdings
- 323,394.38 ZEC as of August 11, 2026
- Zec price q2 move
- $243.35 to $400.09
- Six month net loss
- $37.8 million (H1 2026)
- Zec treasury value
- $129.4 million (digital asset receivable at June 30, 2026)
- Stockholders equity
- $139.3 million
- Unrealized zec gain q2
- $46.0 million
- Zec avg purchase price
- $341.83
- Weighted diluted shares
- 217343013
- Phase3 planned enrollment
- ~270 patients (DKK1-high 2L mCRC, randomized 1:1)
- Ga expense q2 2026 vs 2025
- $4.5 million vs. $1.8 million
- Rd expense q2 2026 vs 2025
- $0.2 million vs. $10.5 million
- Zec share of circulating supply
- ~1.92%
- Phase3 accelerated approval cohort
- ~160 patients (ORR-based)
Price after filing
Close on the filing date to close N calendar days later (from $0.66). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.